Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7911154 | 0.90 | LRRK2 (0.55) | LRRK2SORT1SMARCA2SMARCA4GRM4 | |
| SCHEMBL7899805 | 0.89 | LRRK2 (0.54) | LRRK2GRM4GRM5TYK2HDAC4 | |
| SCHEMBL1794776 | 0.85 | LRRK2 (0.47) | LRRK2SORT1SMARCA2SMARCA4GRM4 | |
| SCHEMBL1795661 | 0.83 | SORT1 (0.46) | LRRK2SORT1SMARCA2SMARCA4GRM4 | |
| SCHEMBL3101805 | 0.82 | SMN1; SMN2 (0.52) | LRRK2GRM4MEN1KMT2ASCN2A | |
| SCHEMBL7913044 | 0.81 | SORT1 (0.58) | SORT1SMARCA2SMARCA4GRM4GRM5 | |
| SCHEMBL1799079 | 0.81 | GRM5 (0.46) | LRRK2SORT1SMARCA2SMARCA4GRM4 | |
| SCHEMBL7906315 | 0.81 | NPC1 (0.56) | LRRK2GRM4GRM5CD38 | |
| SCHEMBL7913781 | 0.81 | ALDH1A1 (0.52) | LRRK2GRM4MEN1KMT2A | |
| SCHEMBL7910114 | 0.81 | LRRK2 (0.53) | LRRK2GRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | LRRK2 1918/4885SORT1 3239/4885SMARCA2 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.